The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries

Leukemia
Verena HoffmannR Hehlmann

Abstract

This population-based registry was designed to provide robust and updated information on the characteristics and the epidemiology of chronic myeloid leukemia (CML). All cases of newly diagnosed Philadelphia positive, BCR-ABL1+ CML that occurred in a sample of 92.5 million adults living in 20 European countries, were registered over a median period of 39 months. 94.3% of the 2904 CML patients were diagnosed in chronic phase (CP). Median age was 56 years. 55.5% of patients had comorbidities, mainly cardiovascular (41.9%). High-risk patients were 24.7% by Sokal, 10.8% by EURO, and 11.8% by EUTOS risk scores. The raw incidence increased with age from 0.39/100,000/year in people 20-29 years old to 1.52 in those >70 years old, and showed a maximum of 1.39 in Italy and a minimum of 0.69 in Poland (all countries together: 0.99). The proportion of Sokal and Euro score high-risk patients seen in many countries indicates that trial patients were not a positive selection. Thus from a clinical point of view the results of most trials can be generalized to most countries. The incidences observed among European countries did not differ substantially. The estimated number of new CML cases per year in Europe is about 6370.

References

Sep 2, 1998·Hematological Oncology·R J McNallyR A Cartwright
Mar 15, 2003·The New England Journal of Medicine·Stephen G O'BrienUNKNOWN IRIS Investigators
Jul 31, 2007·Lancet·Rüdiger HehlmannUNKNOWN European LeukemiaNet
Jun 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hugues de LavalladeDavid Marin
Jun 2, 2009·Nature Reviews. Drug Discovery·Shane Storey
May 5, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fausto CastagnettiGianantonio Rosti
Jun 8, 2010·The New England Journal of Medicine·Giuseppe SaglioUNKNOWN ENESTnd Investigators
Jun 8, 2010·The New England Journal of Medicine·Hagop KantarjianMichele Baccarani
Dec 24, 2010·The New England Journal of Medicine·Claude PreudhommeUNKNOWN France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC)
Mar 23, 2011·Journal of the National Cancer Institute·Carlo Gambacorti-PasseriniDong-Wook Kim
Mar 23, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rüdiger HehlmannSusanne Saussele
Apr 1, 2011·Blood·Gabriele GugliottaUNKNOWN Gruppo Italiano Malattie Ematologiche dell'Adulto CML Working Party
May 18, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Magnus BjörkholmPaul W Dickman
Oct 29, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Gemma GattaUNKNOWN RARECARE working group
Nov 1, 2011·Blood·Alice FabariusUNKNOWN Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) and the German CML Study Group
Jun 14, 2012·Blood·Simona LuattiUNKNOWN Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Working Party on CML
Sep 6, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jorge E CortesCarlo Gambacorti-Passerini
Nov 15, 2013·Journal of the National Comprehensive Cancer Network : JNCCN·Susan O'BrienUNKNOWN Ntational comprehensive cancer network

❮ Previous
Next ❯

Citations

Apr 18, 2016·Journal of Cancer Research and Clinical Oncology·Michael LausekerJoerg Hasford
Mar 31, 2015·Annals of Hematology·Martin HöglundBengt Simonsson
Mar 15, 2016·American Journal of Hematology·Gabriele GugliottaUNKNOWN GIMEMA CML Working Party
Jun 9, 2016·Revista clínica española·J García-Suárez, J J Gil-Fernández
Jun 30, 2016·Expert Review of Hematology·Elisabetta AbruzzeseMichele Baccarani
Jul 9, 2016·Leukemia & Lymphoma·Arjun Datt LawJeffrey Howard Lipton
Jul 3, 2016·Annals of Hematology·Blaise Felix FayeSaliou Diop
Sep 24, 2016·Neoplasia : an International Journal for Oncology Research·Roberto LatagliataGiuliana Alimena
Oct 23, 2016·American Journal of Hematology·Fausto CastagnettiMichele Baccarani
Mar 23, 2017·Hematology·Danijela LekovicAndrija Bogdanovic
Dec 7, 2017·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·David J HermelMojtaba Akhtari
Apr 6, 2019·Expert Opinion on Pharmacotherapy·Rory M Shallis, Nikolai Podoltsev
Feb 6, 2020·Cancers·Hélène LossonMarc Diederich
Feb 9, 2016·Expert Review of Anticancer Therapy·Fabio StagnoPaolo Vigneri
Mar 18, 2017·Journal of Cell Science·Margarethakay ScavelloPascale G Charest
Nov 8, 2018·European Journal of Haematology·Elisabetta AbruzzeseMichael J Mauro
Aug 9, 2020·Journal of Assisted Reproduction and Genetics·Silvina J RiosFrancisca Ferrer-Marín
Feb 23, 2020·Current Hematologic Malignancy Reports·Dakota GustafsonNazanin Aghel
Jan 27, 2019·Biometrical Journal. Biometrische Zeitschrift·Michael Lauseker, Christine Zu Eulenburg
Nov 12, 2019·Frontiers in Oncology·Massimiliano BonifacioFrancesco Di Raimondo
Aug 9, 2019·Annals of Hematology·Monica CrugnolaIsabella Capodanno
Mar 16, 2017·Journal of Cancer Research and Clinical Oncology·Jan GeisslerVerena Sophia Hoffmann
Jan 25, 2019·Leukemia·Michele BaccaraniUNKNOWN International BCR-ABL Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.